ABOS

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) is a clinical-stage biopharmaceutical company founded in 1996 and headquartered in Charlottesville, Virginia. The company went public in July 2021 and focuses exclusively on developing innovative treatments for Alzheimer's disease. Acumen has spent over two decades researching and developing targeted immunotherapy approaches, with its lead drug candidate sabirnetug (formerly ACU193) currently in Phase 2 clinical trials. The company represents a specialized player in the competitive Alzheimer's therapeutics landscape, pursuing a differentiated approach by targeting toxic amyloid-beta oligomers rather than amyloid plaques.